Sun Pharmaceutical Industries Inc. is recalling 12,336 bottles of Buprenorphine Sublingual Tablets (8 mg), a prescription medication used to treat opioid use disorder. The recall was initiated due to deviations from current good manufacturing practices (CGMP), which means the product was not manufactured according to required quality standards. While no injuries or incidents have been reported, the manufacturing issues could potentially impact the quality or consistency of the medicine.
Failure to follow good manufacturing practices can result in medications that do not meet their required quality, purity, or potency standards. This may lead to the medication being less effective or having unintended quality variations.
You have 2 options:
Recall Number: D-0869-2023
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.